Remove DNA Remove Genetic Engineering Remove Protein Remove Scientist
article thumbnail

Accelerating recombinant protein vaccine discovery

Drug Discovery World

While a typical chemisty, manufacturing and controls (CMC) timeline from DNA to Investigational New Drug (IND) application in 2015 would have been approximately 24 months, by 2023 the same pathway was expected to take only 10 months. In particular, we must work to accelerate recombinant protein vaccine development.

Protein 59
article thumbnail

Q&A with Mark Garner: The golden age of cancer research  

Drug Discovery World

A fulfilling part of my job is meeting the scientists, companies, and institutions at the forefront of ground-breaking research that are advancing patient health outcomes. For example, if a patient’s tumour has a particular protein present, called a checkpoint protein, this will reduce the response of T-cells.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Global advances in synthetic biology

Drug Discovery World

The rapidly growing area of synthetic biology – including molecular biology, biotechnology, biophysics, and genetic engineering – is having a marked impact on the drug discovery landscape. Lu Rahman selects some recent synthetic biology innovations and the potential they hold to benefit drug discovery. .

article thumbnail

What to expect from PEGS Europe 2023: Day 2

Drug Discovery World

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Klaus Wagenbauer, PhD, Founder & CEO, Plectonic, on: ‘Programmable DNA-origami-based T cell engagers: PTE’.

article thumbnail

The use of base editing in stem-cell based therapies

Drug Discovery World

Increasing interest in CRISPR-Cas gene editing systems over recent years has delivered innovative developments in precision genome engineering technologies, holding enormous potential for applications across the healthcare sector. 2016/17 saw the emergence of this novel CRISPR-Cas9-based approach.